Marina Konopleva, director of the Leukemia Program and co-director of the Blood Cancer Institute at the Montefiore Einstein Comprehensive Cancer Center, has joined Break Through Cancer, a collaborative medical research foundation that supports teams of scientists as they advance treatments for some of the world’s deadliest cancers.
Johnson & Johnson announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma, regardless of transplant status.
